Literature DB >> 9225795

ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure.

Y Takeishi1, H Atsumi, S Fujiwara, K Takahashi, H Tomoike.   

Abstract

UNLABELLED: Radioiodinated metaiodobenzylguanidine (123I-MIBG), an analog of norepinephrine, has been used to assess cardiac sympathetic nerve activity. Decreased myocardial accumulation and enhanced washout of 123I-MIBG have been reported in patients with congestive heart failure (CHF). The purpose of this study was to determine whether angiotensin converting enzyme (ACE) inhibition reduced 123I-MIBG release and improved cardiac 123I-MIBG accumulation in patients with CHF.
METHODS: Twenty-nine patients receiving conventional treatment for CHF, New York Heart Association (NYHA) functional class 2-3, were studied. Nineteen patients received additional treatment with enalapril, an ACE inhibitor, and 10 patients who were treated with conventional therapy alone were defined as a control group. Iodine-123-MIBG imaging and echocardiography were performed on all patients before treatment and repeated after 9.1 +/- 3.0 mo of treatment. Images were obtained 30 min and 4 hr after injection of 123I-MIBG, and a heart to mediastinum (H/M) ratio was defined to quantify cardiac 123I-MIBG uptake as a fraction of the mean counts per pixel in the heart divided by those in the mediastinum. The washout rate of 123I-MIBG from the heart was calculated as follows: (early counts - delayed counts)/early counts x 100(%).
RESULTS: In patients with enalapril group, the H/M ratio of 123I-MIBG was increased after treatment (early image: 1.60 +/- 0.22 vs. 1.73 +/- 0.28, p < 0.05, delayed image: 1.63 +/- 0.28 vs. 1.82 +/- 0.33, p < 0.01). The washout rate of 123I-MIBG was reduced from 38% +/- 11% to 30% +/- 12% after treatment (p < 0.01). However in the conventional therapy group, the H/M ratios in the early and delayed images (early image: 1.58 +/- 0.31 vs. 1.52 +/- 0.23, delayed image: 1.49 +/- 0.27 vs. 1.49 +/- 0.25) and the washout rate (34% +/- 8% vs. 33% +/- 7%) remained unchanged after treatment. In patients with an increased H/M ratio of enalapril group (n = 13), a left ventricular ejection fraction increased from 48% +/- 12% to 55% +/- 9% (p < 0.01) after treatment.
CONCLUSION: ACE inhibition reduces cardiac 123I-MIBG release and thus lowers cardiac sympathetic nerve activity. Iodine-123-MIBG may be helpful in evaluating the therapeutic effects of ACE inhibition on the cardiac sympathetic nervous system in patients with CHF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9225795

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  32 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 2.  Radionuclide imaging of cardiac autonomic innervation.

Authors:  Sang Yong Ji; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

3.  Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study.

Authors:  Hein J Verberne; Christel Feenstra; W Matthijs de Jong; G Aernout Somsen; Berthe L F van Eck-Smit; Ellinor Busemann Sokole
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

4.  Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

5.  Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide.

Authors:  Shu Kasama; Takuji Toyama; Toshiya Iwasaki; Hiroyuki Sumino; Hisao Kumakura; Kazutomo Minami; Shuichi Ichikawa; Naoya Matsumoto; Tomoaki Nakata; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 9.236

6.  Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients with acute decompensated heart failure.

Authors:  Shu Kasama; Takuji Toyama; Ryuichi Funada; Noriaki Takama; Norimichi Koitabashi; Shuichi Ichikawa; Yasuyuki Suzuki; Naoya Matsumoto; Yuichi Sato; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-30       Impact factor: 9.236

Review 7.  The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.

Authors:  John S Floras; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

Review 8.  What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

Authors:  Fahad Waqar; Stephanie H Dunlap; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2012-12       Impact factor: 5.952

9.  Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy.

Authors:  Noriaki Takabatake; Tsuyoshi Arao; Makoto Sata; Shuichi Abe; Sumito Inoue; Yoko Shibata; Yasuchika Takeishi; Isao Kubota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-23       Impact factor: 9.236

10.  Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor.

Authors:  Myron C Gerson; Lynne E Wagoner; Nancy McGuire; Stephen B Liggett
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.